Pharmaceutical Industry Report - Clinical Report, Drug R&D Report, Pharmaceutical Information

Global Drug R&D Express (May 2023)

Based on the latest data from PatSnap Synapse, Zhihuiya has released the "Global Drug R&D Express (May 2023)". The report includes a total of 75 drugs consisting of: ◉ 18 drugs first approved globally: 5 Small molecule drug (SMD), 4 Monoclonal antibody(mAb), 2 Prophylactic vaccine, 2 Allergen extract, 1 Blood components, 1 Gene therapy, 1 Bispecific antibody, 1 Enzyme, 1 Fusion protein. ◉ 57 drugs under Expedited Review pathways worldwide: 32 Orphan Drug designation, 12 Fast Track designation, 5 Priority review, 4 Breakthrough Therapy designation, 2 Regenerative Medicine Advanced Therapy, 1 Innovative Licensing and Access Pathway (ILAP), 1 Accelerated Approval. The report also highlights: ◼ 5 first approved drugs: Benegrastim, Fezolinetant, Zebituzumab, Perfluorohexyloctane, Beremagene geperpavec ◼ 5 Expedited Review Pathway drugs: Spesolimab, Mefatinib, Resiniferatoxin, Nirsevimab, Fruquintinib, providing a detailed interpretation of the drugs from multiple aspects such as basic information, R&D status, technical barriers, mechanisms of action, clinical trials, and competitive landscape.

Read →

Global Drug R&D Express (Apr. 2023)

Based on the latest data from SYNAPSE, we has released the "Global Drug R&D Express (Apr. 2023)". The report includes a total of 53 drugs consisting of: ◉ 8 drugs first approved globally: 2 Prophylactic vaccine, 2 Small molecule drug (SMD), 1 Monoclonal antibody(mAb), 1 Hematopoietic stem cell, 1 Oligonucleotide antisense, 1 Live biotherapeutic products. ◉ 45 drugs under Expedited Review pathways worldwide: 16 Orphan Drug designation, 12 Fast Track designation, 6 Breakthrough Therapy designation, 4 Priority review, 2 Rare Pediatric Disease designation, 2 Innovative Licensing and Access Pathway (ILAP), 1 Accelerated Approval, 1 Emergency Use Authorization, 1 PRIME (EU). The report also highlights: ◼ 5 first approved drugs: Vilobelimab、R21/Matrix-M、Omidubicel、Reassortant Rotavirus Vaccine、AKEEGA. ◼ 7 Expedited Review Pathway drugs: Remternetug、Sibeprenlimab、HH-003、FCN-159、SAB-176、Resmetirom、CB-011. providing a comprehensive analysis of each, including their snapshot, R&D status, active patents, mechanisms of action, clinical trial information, and competitive landscape.

Read →

Global Drug R&D Express (Mar. 2023)

In March 2023, 41 drugs were approved globally, 53 drugs were under expedited review pathway globally, and about 10 blockbuster drugs made new progress in clinical research.

Read →

Global Drug R&D Express (Feb. 2023)

In February, 2023, 26 drugs were approved globally, 60 drugs were under expedited review pathway globally, and about 10 blockbuster drugs made new progress in clinical research.

Read →

Global Drug R&D 2022 Annual Drug Report

This report provides a comprehensive overview of the first approved drug list worldwide in 2022, and introduces the competitive landscape of 10 milestone new drug developments that have received considerable attention. Based on a synapse database, the report also presents an in-depth analysis of the top 10 hot targets in 2022 and the top 10 potential targets globally for 2023.

Read →

Global Drug R&D Express (Jan. 2023)

In January, 2023, 33 drugs were approved globally, 57 drugs were under expedited review pathway globally, and about 10 blockbuster drugs made new progress in clinical research.

Read →

Global Drug R&D Express (Dec. 2022)

In December, 2022, 40 drugs were approved globally, 65 drugs were under expedited review pathway globally, and about 5 blockbuster drugs made new progress in clinical research.

Read →

Global Drug R&D Express (Nov. 2022)

In November 2022, 31 drugs were approved globally, 54 drugs were under expedited review pathway worldwide, and about 2 blockbuster drugs made new progress in clinical research.

Read →

Global Drug R&D Express (Oct. 2022)

In October, 2022, 18 drugs were approved globally, 60 drugs were under expedited review pathway globally, and about 5 blockbuster drugs made new progress in clinical research.

Read →